Travere Therapeutics (NASDAQ:TVTX - Get Free Report) is set to announce its earnings results before the market opens on Thursday, October 31st. Analysts expect the company to announce earnings of ($0.71) per share for the quarter. Persons interested in registering for the company's earnings conference call can do so using this link.
Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($0.03). Travere Therapeutics had a negative net margin of 82.14% and a negative return on equity of 269.18%. The business had revenue of $54.12 million during the quarter, compared to analysts' expectations of $49.50 million. On average, analysts expect Travere Therapeutics to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Travere Therapeutics Price Performance
Shares of NASDAQ:TVTX traded up $0.13 during midday trading on Thursday, reaching $18.09. 1,273,668 shares of the company's stock traded hands, compared to its average volume of 1,397,422. The company has a fifty day simple moving average of $13.26 and a two-hundred day simple moving average of $9.57. Travere Therapeutics has a 1 year low of $5.12 and a 1 year high of $19.25. The company has a market cap of $1.38 billion, a P/E ratio of -9.62 and a beta of 0.73. The company has a debt-to-equity ratio of 24.96, a quick ratio of 2.99 and a current ratio of 3.04.
Insider Activity at Travere Therapeutics
In other Travere Therapeutics news, SVP William E. Rote sold 4,387 shares of the company's stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $11.52, for a total value of $50,538.24. Following the transaction, the senior vice president now owns 84,455 shares of the company's stock, valued at $972,921.60. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. In other news, SVP William E. Rote sold 4,387 shares of the firm's stock in a transaction on Monday, September 9th. The stock was sold at an average price of $11.52, for a total transaction of $50,538.24. Following the completion of the transaction, the senior vice president now directly owns 84,455 shares in the company, valued at $972,921.60. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Gary A. Lyons sold 40,000 shares of the business's stock in a transaction on Friday, October 4th. The shares were sold at an average price of $14.73, for a total value of $589,200.00. Following the completion of the sale, the director now owns 51,000 shares in the company, valued at $751,230. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 110,707 shares of company stock worth $1,504,312. Insiders own 3.75% of the company's stock.
Wall Street Analysts Forecast Growth
TVTX has been the topic of several research analyst reports. Barclays lifted their target price on shares of Travere Therapeutics from $14.00 to $18.00 and gave the company an "overweight" rating in a research report on Tuesday, October 1st. Guggenheim boosted their price objective on Travere Therapeutics from $23.00 to $41.00 and gave the stock a "buy" rating in a research note on Wednesday, October 9th. Canaccord Genuity Group decreased their target price on Travere Therapeutics from $23.00 to $22.00 and set a "buy" rating on the stock in a research report on Monday, September 30th. Scotiabank began coverage on Travere Therapeutics in a research report on Wednesday, October 16th. They set a "sector outperform" rating and a $23.00 price target for the company. Finally, Citigroup decreased their price objective on Travere Therapeutics from $23.00 to $19.00 and set a "buy" rating on the stock in a report on Friday, September 27th. Two analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company's stock. According to data from MarketBeat, Travere Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $21.38.
Get Our Latest Analysis on Travere Therapeutics
Travere Therapeutics Company Profile
(
Get Free Report)
Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
See Also
Before you consider Travere Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Travere Therapeutics wasn't on the list.
While Travere Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
